Table 3.
In vitro antitubercular activity of title compounds 7a-l against Mycobacterium tuberculosis
| ||||
|---|---|---|---|---|
| Compound | R | R1 | MIC (µg/mL) code
|
|
| H37Rv | MDR-MTB* | |||
| 7a | 4-F | CF3 | 10 | 20 |
| 7b | 3-F | CF3 | 20 | 20 |
| 7c | 3-Cl | CF3 | 20 | NA |
| 7d | 4-CF3 | CF3 | 10 | 15 |
| 7e | 4-Cl | CF3 | NA | NA |
| 7f | 4-OCH3 | CF3 | 10 | NA |
| 7g | 3-OCH3 | CF3 | 20 | 20 |
| 7h | 4-CH | CF3 | 10 | NA |
| 7i | 4-C2H5 | CF3 | NA | NA |
| 7j | 4-Cl | F | NA | NA |
| 7k | CF3 | F | 15 | NA |
| 7l | 3-F | F | 20 | 20 |
Note:
*
These isolates were found to be resistant to the first line antibiotics, rifampicin (1 μg/mL), and isoniazid (0.2 μg/mL).
Abbreviations: MDR-MTB, multidrug-resistant strains of Mycobacterium tuberculosis; MIC, minimum inhibitory concentration; NA, not active.